THE MONSTER STUDY OF STU..TT.E..RING ORPHAN CHILDREN

The Monster Study was a stuttering experiment on 2 dozen homeless orphan children in Davenport, Iowa,USA  in 1939 conducted by Wendell Johnson at the University of Iowa. Johnson chose one of his graduate students, Mary Tudor, to conduct the experiment and he closely supervised & observed her research. After placing the children in control and experimental groups, Tudor gave positive speech therapy to half of the children, praising the fluency of their speech, and negative speech therapy to the other half, belittling the children for every speech imperfection and telling them they were stutterers. Many of the normal speaking orphan children who received negative therapy in the experiment suffered negative psychological effects and some retained speech problems during the course of their life. Dubbed “The Monster Study” by some of Johnson’s peers who were horrified that he would experiment on orphan children to prove a theory, the experiment was kept hidden for fear Johnson’s reputation would be tarnished in the wake of human experiments conducted by the Nazis during World War II. The University of Iowa publicly apologized for the Monster Study in 2001.

Sourced & published by Henry Sapiecha

Head-worn device uses sonar to rapidly diagnose stroke
A team of radiologists and retired US Navy sonar experts have used technology developed for submarines as the basis for a new device which offers quick detection, diagnosis and monitoring of stroke. Combined with a portable laptop based console, the head-worn device enables different types of stroke and brain injury to be discovered and located, differentiating normal blood flow from life threatening conditions and delivering an initial diagnosis in under a couple of minutes. Read More

Received & published by Henry Sapiecha

Capsaicin Can Act as Co-Carcinogen,

Study Finds; Chili Pepper Component

Linked to Skin Cancer

Science (Sep. 3, 2010) — A study in the journal Cancer Research by researchers at The Hormel Institute, University of Minnesota, links capsaicin, a component of chili peppers, to skin cancer. While the molecular mechanisms of the cancer-promoting effects of capsaicin are not clear and remain controversial, the new research has shown a definite connection to formation of skin cancer through various laboratory studies.

Ann Bode, professor in the institute’s Cellular and Molecular Biology Research Section, led the research team on this study along with colleagues Mun Kyung Hwang and Zigang Dong.

Capsaicin, widely consumed worldwide in foods that contain chili peppers, is also used in topical creams for pain relief and its role in cancer development is controversial. Capsaicin has been shown to induce apoptosis (cell death) in cancer cells. However, research findings have also shown that it can also act as a carcinogen, especially at the tumor promotion stage.

Bode says the possibility that capsaicin induces inflammation and may affect cancer development is a critical result of the study. “Most notably, the results raise concerns that a natural compound found in hot peppers used in over-the-counter topical pain remedies might increase skin cancer risk,” Bode says.

The study’s key findings include:

• The co-carcinogenic effect of capsaicin appears to be mediated through the epidermal growth factor receptor (EGFR) and not the transient receptor potential vanilloid subfamily member 1 (TRPV1), a known pain receptor.
• Topical application of capsaicin on the dorsal skin of wildtype or TRPV1 knockout mice induced tumors in both types but more and larger skin tumors in the knockout mice.
• A known inflammatory enzyme, cyclooxygenase-2 (COX-2) was highly elevated following treatment with capsaicin.

Other researchers working with Bode on this study included Sanguine Byun, Nu Ry Song, Hyong Joo Lee and Ki Won Lee.

Funding for this research was provided by The Hormel Foundation, National Cancer Institute and the Korean Research Foundation.

Editor’s Note: This article is not intended to provide medical advice, diagnosis or treatment.

Sourced & published by Henry Sapiecha

Sourced & published by Henry Sapiecha

Deathstalker Scorpion Venom

Could Improve Gene Therapy

for Brain Cancer

Science (Aug. 11, 2010) — An ingredient in the venom of the “deathstalker” scorpion could help gene therapy become an effective treatment for brain cancer, scientists are reporting. The substance allows therapeutic genes — genes that treat disease — to reach more brain cancer cells than current approaches, according to the study in ACS Nano.

Miqin Zhang and colleagues note that gene therapy — the delivery of therapeutic genes into diseased cells — shows promise for fighting glioma, the most common and most serious form of brain cancer. But difficulties in getting genes to enter cancer cells and concerns over the safety and potential side effects of substances used to transport these genes have kept the approach from helping patients.

The scientists describe a new approach that could solve these problems. Key ingredients of their gene-delivery system are chlorotoxin, the substance in deathstalker scorpion venom that can slow the spread of brain cancer, and nanoparticles of iron oxide. Each nanoparticle is about 1/50,000th the width of a human hair. In tests on lab mice, the scientists demonstrated that their venom-based nanoparticles can induce nearly twice the amount of gene expression in brain cancer cells as nanoparticles that do not contain the venom ingredient. “These results indicate that this targeted gene delivery system may potentially improve treatment outcome of gene therapy for glioma and other deadly cancers,” the article notes.

Sourced & published by Henry Sapiecha

New ‘hand’ may alleviate phantom pain

JENA, Germany (UPI) — Amputees suffering from “phantom pain” may get relief from a modified prosthetic that can convince the brain the body part still exists, researchers say.

Scientists at the University of Jena in Germany say phantom pain often lasts for years, and sometimes for a lifetime, often putting amputees at risk of mediation addiction from high dosages of painkillers, a university release said Friday.

Researchers say they’ve produced a modified prosthetic hand than can reduce phantom pain following amputation by using a stimulation unit in the hand’s cuff connected to the remaining part of the upper arm.

Modern prosthetic hands have pressure sensors meant to regulate the strength of grip of the artificial hand depending on what the wearer is trying to pick up, such as a raw egg or a hammer.

The stimulation unit in the modified hand takes feedback from the sensors and “talks” to the wearer’s brain, Dr. Gunther Hofmann of the Jena Department for Trauma, Hand and Reconstructive Surgery says.

“Our system is now able to transmit this sensory information from the hand to the upper arm,” Hofmann says.

Brain structures responsible for processing sensory information coming from the lost body part are “out of work” following an amputation and try to reorganize themselves, often leading to sensations of pain in a “phantom” hand, the Jena researchers say. By giving the appropriate brain structure sensory input from the “hand” it is meant to control, the reorganization can be prevented or reversed, thus eliminated phantom pain, they say.

Copyright 2010 by United Press International

Sourced & published by Henry Sapiecha

Saving Eyes

Ocular Oncologists Inject Drug Into Eye

To Starve Tumors And Save Sight

October 1, 2008 — Ocular oncologists adopted a drug originally intended to treat colon cancer as a treatment for cancers in the eye as well as macular degeneration. The drug reduces abnormal blood vessel growth, which starves tumors and stops blood vessels from leaking. This interrupts the processes that would, if not stopped, greatly damage patients’ vision.

Whether it’s cancer or macular degeneration, many times patients must face the reality that they will go blind. Now, a new treatment is helping save their sight.

The first thing everyone notices about Dove Karn is her beautiful blue eyes — and it was in Central Park where she came to terms with the fact that she had melanoma in one of those very eyes.

Her tumor was treated with radiation — but the side effects could destroy her vision. Ocular oncologist Paul Finger turned to a new drug to stop Dove’s vision from slipping away.

“It’s a real paradigm shift — like antibiotics were for infections,” says Paul Finger, M.D., an ocular oncologist at the New York Eye Cancer Center in New York City. “This anti-blood-vessel drug is saving people’s vision.”

Avastin is a shot given directly into the eye. It starves the tumor by stopping the growth of abnormal blood vessels that normally would feed the tumor.

“Avastin stops new blood vessels from growing, but it also prevents new and old blood vessels from leaking — and the leaking is what takes away most of the patient’s vision,” Dr. Finger said.

Dove will need to get shots every 6 to 8 weeks, indefinitely — but she says it’s worth it.

“This year was the year that I could say I’m in remission,” Karn said. “I have a full-time teaching job. My children are fabulous — life is wonderful right now.”

ABOUT CANCER IN THE EYE: Ocular melanoma — eye cancer — is a particularly rare and aggressive form of cancer that attacks the pigment cells in the retina. There are essentially two types of intraocular melanoma: low-grade tumors, which grow slowly and rarely metastasize, and high-grade tumors, which grow more quickly and metastasize at a very early stage. Once a tumor metastasizes, the cancer spreads quickly to the liver and other organs, and a patient has only 6 to 12 months to live in the worst cases, although some can survive for as long as 5 years. The National Eye Institute estimates some 2,000 newly diagnosed cases of ocular melanoma occur per year in the United States and Canada –roughly seven in one million people. It affects people of all ages and races, and is not hereditary. Ocular melanoma kills nearly half of those who develop it.

Sourced & published by Henry Sapiecha

Nanotechnology and stem cells rejuvenate arteries

A combination of nanotechnology and adult stem cells has been shown to destroy arterial plaque atherosclerosis in the hearts of pigs. Animals that received stem cells also showed signs of new blood vessel growth and restoration of artery function, according to the study reported at the American Heart Association’s Basic Cardiovascular Sciences 2010 Scientific Sessions.

The study was conducted at the Department of Internal Medicine and Research Center of Regenerative Medicine, Ural State Medical Academy in Yekaterinburg, Russia. Nanoparticles were infused into the heart of pigs, along with adult stem cells, then heated by laser light until they burned away arterial plaque. The volume of plaque shrunk an average of 28.9 percent immediately after treatment across the three treatment groups, and six months later it had declined 56.8 percent on average. In the control group, plaque volume increased an average of 4.3 percent.

“Biophotonics (light therapy), plasmonics (plasma therapy), stem cell therapy and nanotechnology might someday offer a completely novel treatment to reduce artery plaque build-up,” said lead author and research manager Alexandr Kharlamov. “Nanoburning in combination with stem cell treatment promises demolition of plaque and functional restoration of the vessel wall.”

This new approach may one day replace angioplasty, a common treatment for atherosclerosis, in which a balloon-tipped catheter is threaded into a blocked artery and the balloon is inflated to restore blood flow. The balloon squeezes plaque against the artery wall, but does not eliminate it.

Sourced & published by Henry Sapiecha

Study: Music training ‘primes’ the brain

EVANSTON, Ill. (UPI) — Musical instruction can “prime” the brain to improve human skills in language, speech, memory and attention, U.S. researchers say.

A study at Northwestern University found the effects of musical training on the nervous system can build meaningful patterns important to all types of learning, ScienceDaily.com reported Tuesday.

Researchers studied music training’s effect on neuroplasticity, defined as the brain’s ability to adapt and change as a result of training and experience over the course of a person’s life.

An active engagement with musical sounds not only enhances neuroplasticity, Nina Kraus, director of Northwestern’s Auditory Neuroscience Laboratory, said, but also creates permanent patterns important to all learning.

“The brain is unable to process all of the available sensory information from second to second, and thus must selectively enhance what is relevant,” Kraus said.

“A musician’s brain selectively enhances information-bearing elements in sound,” Kraus said, and “the nervous system makes associations between complex sounds and what they mean.”

These efficient sound-to-meaning connections are important not only for music but for other aspects of communication, she said.

“The effect of music training suggests that, akin to physical exercise and its impact on body fitness, music is a resource that tones the brain for auditory fitness,” the study said.

Copyright 2010 by United Press International

Sourced & published by Henry Sapiecha

Protein could battle Alzheimer’s disease

NEW YORK (UPI) — U.S. researchers say they are looking at a new approach to treating Alzheimer’s disease with a protein thought to extend lifespan in laboratory animals.

Scientists at the Massachusetts Institute of Technology said that in mice prone to developing Alzheimer’s, activating a protein called sirtuin suppressed the disease and destroying the protein made the disease much worse, The New York Times reported.

The finding raises the hope that Alzheimer’s, and possibly other neurodegenerative diseases like Parkinson’s and Huntington’s, could be treated with drugs that activate sirtuin, researchers say.

“We think it is a scientifically compelling story that ties the sirtuins to the biology of Alzheimer’s disease,” said Dr. Dennis J. Selkoe, an Alzheimer’s expert at Harvard Medical School who was not a part of the study.

Drugs that activate sirtuin already exist, including resveratrol, a minor ingredient of red wine and other foods.

One drug company, Sirtris, is in preclinical trials with sirtuin-activating drugs.

“We think it has very significant potential in neurodegenerative diseases,” Sirtris Chief Executive Officer George P. Vlasuk said.

Copyright 2010 by United Press International

Sourced & published by Henry Sapiecha